A specific protein called TEAD1 is an important regulator of tumour migration in glioblastoma, the most common brain tumour in adults, and deactivating this protein may stop tumour cells from migrating away from the main tumour mass, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 1 in the journal Nature Communications.

The data garnered through this study may help increase the success rate and overall survival time after surgery for patients who are afflicted with this devastating form of tumour.

Glioblastoma carries a dismal prognosis, despite aggressive treatment.

One of the main reasons glioblastoma cannot be cured is because of the tumour's unusual ability to rapidly crawl and spread through the patient's brain, a property referred to as "migration" or "infiltration."

While many chemotherapy drugs can stop tumour cells from multiplying, treatment options to stop tumour cells from migrating do not yet exist.

The diffusely infiltrative nature of glioblastoma tumour growth is a challenge for surgical therapy because infiltrative cells inevitably extend beyond the margin of apparently non-tumorous tissue around a tumour mass that has been surgically removed.

Because the intrinsic biology of these cells is poorly understood and their movement is so devastating, there is a critical need for better understanding of the process of migration.

Previous research has implicated several transcription factors (special types of proteins that bind directly to DNA at specific sites along the genome to either activate or shut off particular genes) in the regulation of glioblastoma tumour growth and migration, but most of these studies were done in a petri dish.

The environment of tumour cells in a dish is very different from the one within the patient's diseased brain.

In a dish, cells are artificially stimulated to grow and divide, which has an impact on their movement and activity.

Additionally, cells inside a dish lack the actual structural elements present inside the brain along which tumour cells migrate.

"Our study is one of the first to take human patient glioblastoma cells directly from the tumour immediately after surgery and isolate the most aggressive tumour subclones--the glioma stem cells--to specifically characterise the machinery responsible for tumour migration," said Nadejda Tsankova, MD, PhD, Associate Professor of Pathology and Neuroscience at the Icahn School of Medicine at Mount Sinai and senior author of the paper. "We found that the transcription factor TEAD1 directs the activity of genes responsible for tumour migration and, particularly, our research implicates the AQP4 gene as one of TEAD1's direct pro-migratory partners."

The team first characterised the epigenetic landscape (the machinery responsible for turning genes on and off) of aggressive glioblastoma cells and discovered a signature whose footprints relate specifically to tumour migration.

After identifying TEAD1 as having the most enriched footprint in this migratory signature, researchers used the gene-editing technology known as CRISPR to delete TEAD1 from tumour cells.

When TEAD1 was absent, cells lost their ability to migrate, both in vitro (in a petri dish) and in vivo (in the brain), and their migratory genes became inactive.

When they added TEAD1 back, migratory abilities were partially restored.

Jessica Tome-Garcia, PhD, Senior Postdoctoral Fellow in the Tsankova Research Laboratory at Mount Sinai and leading experimental researcher of this project, then tested several potential places on the genome where TEAD1 may be binding in order to signal migration.

One unexpected site of binding was at the gene encoding the AQP4 protein, which is responsible for controlling water movement that allows cells to change their shape as they penetrate through the brain.

The team found that tumour cells without TEAD1 activity (the ones that could no longer migrate) turned the AQP4 gene off.

However, if cells were provided with AQP4, either by giving them TEAD1 or by giving them AQP4 directly, they started migrating again.

"Our study data provides convincing evidence that TEAD1 signals through AQP4 to promote tumour migration and furthermore, that if we can inhibit activity of TEAD1, we can potentially stop tumour cells from migrating away from the main tumour mass," said Dr. Tsankova. "This newfound information has important implications for brain tumour treatment, potentially increasing the success rate of removing the entire tumour during surgery or at least prolonging the time it takes for the tumour to come back."

Dr. Tsankova's research team is actively testing TEAD1 drug inhibitors to see if they stop tumour cells from migrating in a dish or in laboratory animals, with the hope that one day in the near future, they will be able to offer new anti-migratory treatments for patients with infiltrative brain tumours.

Source: The Mount Sinai Hospital / The Mount Sinai School of Medicine